Biotech Startups

Aleph Farms develops cultivated meat, growing beef steaks from cow cells using tissue engineering technology, and produced the world's first cultivated thin-cut and ribeye steaks. The company received the world's first regulatory approval for cultivated beef and markets its products under the Aleph Cuts brand.

8 investors

Alto Neuroscience is a clinical-stage biopharmaceutical company developing biology-driven medicines for neuropsychiatric conditions, using measurements of brain biology to predict clinical response and identify patients likely to benefit from its drug candidates. Its initial focus areas include major depressive disorder, bipolar depression, and schizophrenia.

8 investors

Aralez Bio uses an enzyme-based (biocatalysis) platform to produce noncanonical amino acids and protected amino acid building blocks for peptide therapeutic discovery and manufacturing teams. It positions its enzymatic process as a greener alternative to traditional amino acid synthesis and manufactures at scale in Berkeley, California.

8 investors

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers. Its pipeline centers on its lead candidate firmonertinib (formerly furmonertinib) and novel oncology therapeutics such as next-generation antibody drug conjugates.

8 investors

Atomwise uses artificial intelligence and machine learning to discover novel small-molecule drugs, with a current focus on developing treatments for immune and inflammatory diseases.

8 investors

Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies. The company operates in the biotech and respiratory drug development space.

8 investors

Beam Therapeutics develops gene-editing medicines, particularly base editors and precision genome editing technologies, to create lifelong cures for patients with serious genetic diseases. The company works across multiple therapeutic areas to advance precision medicine treatments at the molecular level.

8 investors

BioOrbit produces pharmaceutical-grade crystals in microgravity environments via space-based facilities, enabling development of biologic drugs and treatments for patients. The company bridges orbital research with terrestrial medicine to make advanced pharmaceutical manufacturing accessible beyond hospital settings.

8 investors

Bioptimus is an AI-first biotech company developing a universal AI foundation model that connects biology across scales, from molecules and cells to tissues and whole organisms, to support biomedical research and innovation. It applies machine learning to areas such as computational pathology, genomics, and drug discovery.

8 investors

C16 Biosciences produces high-value lipid ingredients using fermentation of naturally occurring microorganisms for manufacturers of beauty, personal care, home care, and food products. The company's biomanufacturing platform enables sustainable production with 250x greater land efficiency than traditional ingredient sources.

8 investors

Causaly builds an agentic AI platform for life sciences R&D that retrieves and reasons over scientific evidence, using a scientific knowledge graph and specialized AI agents to support target identification, indication discovery, and regulatory evidence validation. It serves biomedical and pharmaceutical enterprises across the R&D pipeline, from early research through clinical development and post-market.

8 investors

Chemify builds automated chemical synthesis systems combining chemistry, AI, and robotics to digitize molecular design and manufacturing. The company serves pharmaceutical, materials, and chemical discovery partners seeking faster and more scalable access to novel molecules and drugs.

8 investors

Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies. The company serves cancer patients and their caregivers globally.

8 investors

Cyrus Bio is a computational drug discovery company that uses protein design, deep mutagenesis, and modeling algorithms to engineer naturally occurring proteins into therapeutics. Its pipeline targets severe autoimmune, gastrointestinal, metabolic, and respiratory conditions, including IgG-depletion and cytokine-based biologic candidates.

8 investors

Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.

8 investors

Evommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief. The company runs discovery and development programs with a focus on immunology.

8 investors

GALY develops biocrafted alternatives to conventionally extracted materials like cocoa and cotton, positioning grown products as sustainable replacements for industries reliant on extractive supply chains.

8 investors

Generation Lab offers an at-home epigenetic aging test (SystemAge) that measures 460 biomarkers across 21 organs and systems using DNA methylation, delivering a personalized aging report and action plan for consumers. It uses a needle-free blood collection device and connects users to a network of longevity clinics for follow-up consultations and retesting.

8 investors

Genome Medical provides telehealth-enabled genetic services, including genetic counseling, genetic testing, and clinical trial matching, with a focus on individuals with rare conditions. It partners with hospitals and health systems, life sciences organizations, and genetic testing labs to expand patient access and improve care.

8 investors

Glyphic Biotechnologies develops ProSE™, a high-throughput de novo protein sequencing technology for analyzing proteomes with single-molecule sensitivity. The platform serves research and therapeutic development in proteomics and drug discovery.

8 investors

Heartflow provides an AI-based analysis that converts a coronary CTA scan into a personalized 3D model of the heart, assessing anatomy and physiology to help diagnose and manage coronary artery disease (CAD). Its platform, Heartflow One, is used by cardiologists and clinicians to guide diagnosis and treatment decisions for patients.

8 investors

Hummingbird Bioscience develops antibody-based therapeutics, including antibody-drug conjugates (ADCs), using proprietary linker-payload and biologics discovery platforms. Its pipeline targets oncology and autoimmune diseases, aiming at precision medicine for patients who do not respond to current treatments.

8 investors

Kanvas Bio operates a full-stack microbiome drug discovery platform, using a spatial mapping engine to image host-microbiome interactions and in-house manufacturing to produce live biotherapeutics. Its therapies are designed to modulate host immunity for applications including immunotherapy and malnutrition treatments.

8 investors

Manus Bio uses industrial biotechnology and engineered microbial cell factories to produce "BioAlternatives" — sustainable versions of molecules normally sourced from petrochemicals, agriculture, or animal husbandry — and offers a scale-up platform covering cell factory design through biomanufacturing. Its products include sweeteners and flavor/fragrance ingredients supplied to food and consumer goods companies such as Tate & Lyle and Givaudan.

8 investors